Tokyo Midtown Advanced Medical Research Institute: World's first paper on joint clinical research into the design and implementation of immunochemotherapy for unresectable pancreatic cancer published in the online edition of the Journal for ImmunoTherapy of Cancer

The Jikei University School of Medicine, in collaboration with the Tokyo Midtown Advanced Medical Research Institute, Juntendo University, Kanazawa Medical University, and Osaka University Graduate School of Medicine, conducted a phase I clinical trial of "WT1 dendritic cell vaccine therapy in combination with standard chemotherapy for unresectable pancreatic cancer."

This research, devised and conducted by Dr. Shigeo Koido, then professor of gastroenterology and hepatology at the Jikei University School of Medicine, and his colleagues, is the world's first immunochemotherapy for inoperable pancreatic cancer (stage 3 or 4).

A paper on this research has been published in the online edition of the Journal for ImmunoTherapy of Cancer. The Tokyo Midtown Advanced Medical Research Institute collaborated in a joint clinical research project to create the WT1 dendritic cell vaccine used in this therapy.

The online version of the Journal for ImmunoTherapy of Cancer is available here
https://jitc.bmj.com/content/12/10/e009765.long
*This paper is in English.

For more details, please see below.
https://www.amcare.co.jp/wp-content/uploads/2024/11/PR_release_sentan_amc20241121.pdf
*From Advanced Medical Care Inc. NEWS RELEASE

The information on this page is current as of January 2024, 11.